Progression-Free Survival

← Back to Glossary

Definition

Progression-free survival (PFS) is the time from treatment start until disease worsens or death, whichever comes first. It measures how long treatment delays cancer growth but doesn't measure how long patients live overall.

Correct Scientific Usage

Researchers use progression-free survival as an earlier endpoint than overall survival in cancer trials. PFS results become available sooner because disease progression typically occurs before death, allowing faster trial completion. PFS is valuable when treatments may benefit patients through delayed progression even if overall survival isn't extended.

Scientists recognize PFS as a surrogate endpoint requiring careful interpretation. Improved PFS doesn't automatically mean improved overall survival—cancer may progress differently after initial control, subsequent treatments may differ between groups, or treatment toxicity may offset progression delay.

Common Misunderstandings

Progression-free survival is often conflated with overall survival when they measure different outcomes. A treatment delaying progression (improving PFS) doesn't necessarily extend life (improve overall survival) if the treatment period is followed by equivalent survival from progression to death.

There's confusion about what progression-free survival means for patients. Time without progression sounds beneficial, but if that time involves severe treatment side effects or doesn't translate to living longer overall, the clinical benefit is uncertain.

Why It Matters

Understanding progression-free survival prevents assuming delayed progression automatically means longer life. It explains why regulatory agencies increasingly require overall survival data even when progression-free survival improves, and why patients and clinicians must weigh progression delay against treatment burden when overall survival benefits aren't demonstrated.

References

  • Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology, JAMA Internal Medicine
  • Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology, Journal of Cancer

← Back to Glossary